An 88-year-old female was admitted with autoimmune hemolytic anemia (AIHA). Coagulation test revealed severe prolongation of activated partial thromboplastin time (APTT). APTT cross-mixing test with patient plasma and normal plasma demonstrated an inhibitory pattern. Several intrinsic coagulation factor activities, particularly factor IX, showed remarkable decreases, and the inhibitor titers for coagulation factors VIII and IX were elevated. Although AIHA with existing antiphospholipid (aPL) antibodies was diagnosed initially, purpura developed on extremities intermittently during the clinical course. Considering the possibility of coexisting acquired hemophilia, APTT cross-mixing test with patient's plasma and equal amount of the recombinant factor VIII product instead of normal plasma was performed. The APTT value on equal mixing samples with patient plasma and recombinant factor VIII product was decreased to within the normal range, and coagulation factor IX activity was restored. These results indicate that the recombinant factor VIII product had a neutralizing effect on aPL antibodies. We concluded that recombinant factor VIII product may lead to the repair of incorrect results from the APTT-dependent diagnostic system in the presence of aPL antibodies.
Introduction
The two major autoimmune diseases demonstrating activated partial thromboplastin time (APTT) prolongation and normal prothrombin time (PT) on coagulation screening are antiphospholipid (aPL) antibody syndrome (APS) and acquired hemophilia. APTT cross-mixing test demonstrates an inhibitory pattern in both diseases, and the diagnoses are made according to clinical findings and the measurement of aPL antibodies or coagulation factor activities.
Several cases of coexistent APS and acquired hemophilia have been reported; however, the mechanisms underlying the concurrent development of both diseases are yet to be well clarified. Herein, we report a case of autoimmune hemolytic anemia (AIHA) with aPL antibodies, in which the existence of acquired hemophilia was excluded by APTT cross-mixing test with a recombinant factor VIII product.
Case report
An 88-year-old female presented to the outpatient clinic in August 2013. Her chief complaint was a 2-month history of stridor on walking.
She had a medical history of mucosa-associated lymphoid tissue lymphoma of the lung from 71 years of age and anemia diagnosed at was excluded due to the absence of prothrombin antibody.
The patient's clinical course is shown in figure 2 . Therapeutic intervention for AIHA was performed, with oral prednisolone (PSL) therapy (15 mg/day) started in August 2013, considering her advanced age. Diuretics were initiated to treat heart failure. After starting PSL therapy, hemolysis and anemia gradually improved.
In order to avoid side effects associated with PSL, the dose of PSL was reduced gradually to 8 mg/day by replacing with azathioprine.
At the beginning of 2014, the hemoglobin level had increased to > 8 g/dl without red blood cell transfusion; however, the complement titer, coagulation factor IX activity, and inhibitor level of coagulation (Fig. 1 B) , with similar purpura intermittently observed on the extremities. Accordingly, a hemostatic agent was used to continuously treat her purpura.
To investigate the cause of emerging purpura, we considered the possibility of coexisting acquired hemophilia. We particularly focused on acquired hemophilia B as coagulation factor IX had the lowest titer.
We supposed that recombinant factor VIII product, where factor IX did not exist, could bind to aPL antibodies, resulting in the decrease of the aPL antibodies by neutralization in the test tube study. We hypothesized that factor IX activity might emerge by elimination of aPL antibodies with recombinant factor VIII product, while factor IX activity might not increase in the existence of acquired hemophilia B disease in the same study. APTT cross-mixing test [2] with recombinant factor VIII product instead of control plasma was performed, in which we attempted to remove the effect of aPL antibodies. Kogenate® that the recombinant factor VIII product had a neutralizing effect on aPL antibodies in the APTT system. When measuring coagulation factor IX activity and factor IX inhibitor titers by using mixed sample of plasma and the recombinant factor VIII product in equal proportions, factor IX activity increased to 10% level, while the factor IX inhibitor titer did not obviously change (Fig. 1 D) . These results indicate that the recombinant factor VIII product had the ability to diminish the falsenegative reaction caused by the aPL antibodies on the APTT analysis system. We therefore excluded acquired hemophilia B complication by confirming the emergence of factor IX activity in the test tube study. Regarding the coagulation test performed in the present case, several intrinsic coagulation factor activities, particularly factor IX, showed remarkable decreases, and the inhibitor titers for coagulation factor VIII and IX were elevated. When detecting decreases in the activity of numerous coagulation factors or the presence of coagulation factor inhibitors, the false phenomenon caused by aPL antibodies due to modulation of the APTT system should be considered [2, 4] . As the APTT system depends on phospholipids, decreases in coagulation factors or the detection of coagulation inhibitors may be attributable to inhibition of phospholipid activity by aPL antibodies. One solution is to use the dRVVT test [5, 6] ; however, careful consideration is required to arrive at the correct diagnosis. To confirm the phospholipid dependence, PNP or hexagonal phase phospholipid neutralization procedure (Staclot ® LA) is generally used, in which we selected PNP.
In terms of the differential diagnoses for aPL syndrome and acquired hemophilia, cases with the coexistence of aPL syndrome and acquired hemophilia have been reported in recent years [7] [8] [9] [10] , in most of which the bleeding symptom was the major event irrespective of fulfillment of the criteria for aPL syndrome. The identification of the coexistence of aPL and anti-coagulation factor antibodies is limited by the APTT-dependent diagnostic system [11, 12] . The present case (Fig. 1 C) .
This result indicates that the recombinant factor VIII product had the ability to normalize the APTT of the patient sample. When using equal volumes of patient plasma and the recombinant factor VIII product, factor IX activity increased to 10%, while the inhibitor titer of factor IX remained at 24 BU/ml in the revised calculation (Fig. 1 D) . As the recombinant factor VIII product contained no other coagulation factors, the increasing factor IX activity indicates that the factor IX activity of the initial patient sample was a false-negative result and the recombinant factor VIII product had the ability to correct this false-negative phenomenon. In other words, recombinant factor VIII product may lead to the repair of incorrect results from the APTT-dependent diagnostic system in the presence of aPL antibodies.
We showed no complication of hemophilia B in the present case; on the other hand, we did not exactly show whether hemophilia A was complicated or not. However, acquired hemophilia B was more likely the cause than acquired hemophilia A if considering the complication of acquired hemophilia, due to the fact that the level of coagulation factor VIII remained as 7%, which was higher than the level of factor IX activity, and the inhibitor titer of coagulation factor VIII was less than that of coagulation factor IX.
Chromogenic assay is another method for the evaluation of coagulation factors, including factor VIII and IX. There are several reports on the comparison between one-stage APTT-based assay and chromogenic assay for assessing coagulation factor levels in patients with anti-PL antibodies, in some of which the chromogenic assay is recommended. The one-stage APTT-based assay may be influenced by nonspecific inhibitors [13] , and Chandler et al. report that chromogenic assay is better than one-stage APTT-based assay for measuring factor VIII activity in lupus inhibitor-containing samples [14] . In addition, a few cases showed that aPL antibody influenced the one-stage APTT-based assay but not the chromogenic assay [15] , implying that the chromogenic assay is an optimal test for evaluating coagulation factor VIII and IX activities in patients with anti-PL antibodies.
We concluded that the present case did not have acquired hemophilia B. To the best of our knowledge, this is the first report of the use of the APTT cross-mixing test using coagulation factor products, including recombinant factor VIII, as a dilution reagent instead of normal plasma.
As the present report involves a single case, further studies are required to clarify the effects of autoantibodies in patients with APS. 
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